Vaccitech to join Brookfield’s Harwell Campus

Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced it has signed a lease for 31,000 sq. ft within the Zeus development at Harwell Science and Innovation Campus. The Company plans to relocate its headquarters from Oxford in Spring 2022.

Read full release here.